Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study

Myriad Genetics' Precise Minimal Residual Disease (MRD) test demonstrated high sensitivity and pan-cancer applicability in detecting circulating tumor DNA (ctDNA), according to interim data from the MONSTAR-SCREEN-3 study. The study showed 100% ctDNA detection at baseline and the ability to detect tumor fractions as low as 0.0001%, outperforming first-generation MRD tests, particularly in low-shedding tumors. These findings support the use of Precise MRD for real-time ctDNA monitoring and early recurrence detection across various cancer types, potentially improving patient outcomes and treatment strategies; MYGN is currently trading up 2.91%.

Analysis

Myriad Genetics (MYGN) has reported compelling interim data from its MONSTAR-SCREEN-3 study for the Precise Minimal Residual Disease (MRD) test, indicating high sensitivity and broad pan-cancer applicability in detecting circulating tumor DNA (ctDNA). The study, conducted with Japan's National Cancer Center Hospital East, demonstrated 100% ctDNA detection at baseline and the ability to identify tumor fractions as low as 0.0001%. Notably, this ultra-sensitive, whole-genome sequencing (WGS) based assay detected ctDNA in 60% of post-surgery ctDNA-positive patients where levels were undetectable by less sensitive methods, outperforming first-generation MRD tests, particularly in low-shedding tumors such as breast and renal cancers. The findings also support Precise MRD's utility in predicting pathological complete response to neoadjuvant chemotherapy and identifying patients with significantly worse disease-free survival based on residual ctDNA after surgery. This positions the test, which tracks up to 1,000 tumor-specific variants, as a potentially powerful tool for real-time ctDNA monitoring and early recurrence detection across numerous cancer types. Currently, the Precise MRD test is available for research collaborations and is undergoing further validation in several major clinical studies, with Myriad's stock (MYGN) trading up 2.91% to $4.31 on the news.

Key Decisions for Investors

• The positive interim data for Myriad's Precise MRD test signals a significant potential growth driver in the cancer diagnostics market; investors should closely monitor its continued clinical development and competitive positioning.
• Key upcoming catalysts include further clinical trial readouts and progress towards regulatory approvals for the Precise MRD test, which will be critical for its commercial viability and potential impact on Myriad's valuation.
• While the initial market response to the data is positive, the test's current research-use status and ongoing validation phase mean investors should carefully weigh the timeline and inherent risks of clinical development and market adoption before making significant investment decisions.